NCT06914479View on ClinicalTrials.gov

Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

November 1, 2030

Study Completion Date

November 1, 2030

Conditions
Recurrent Diffuse Hemispheric Glioma, H3 G34-MutantRecurrent Malignant Brain NeoplasmResectable Brain Neoplasm
Interventions
GENETIC

Ad-hCMV-Flt3L

Given via injection

GENETIC

Ad-hCMV-TK

Given via injection

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

OTHER

Survey Administration

Ancillary studies

PROCEDURE

Tumor Resection

Undergo standard of care tumor resection

DRUG

Valacyclovir

Given PO

Trial Locations (1)

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER